Brian Elsbernd Sells 25,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Brian Elsbernd sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the sale, the insider now owns 124,433 shares in the company, valued at approximately $2,045,678.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX traded down $0.33 during trading hours on Thursday, hitting $15.94. The stock had a trading volume of 1,172,161 shares, compared to its average volume of 1,517,481. The firm has a market cap of $1.88 billion, a P/E ratio of 26.67, a P/E/G ratio of 1.10 and a beta of 0.92. The company’s fifty day simple moving average is $14.96 and its 200 day simple moving average is $14.17. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.09 and a 12-month high of $18.22.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.04. The business had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. As a group, sell-side analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. Oppenheimer reiterated an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a report on Wednesday. Bank of America started coverage on Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They set a “buy” rating and a $23.00 price target on the stock. Citigroup started coverage on Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They set a “buy” rating and a $27.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $26.43.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Advisory Services Network LLC raised its position in Catalyst Pharmaceuticals by 260.2% in the first quarter. Advisory Services Network LLC now owns 1,801 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 1,301 shares during the period. Parkside Financial Bank & Trust acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $31,000. VisionPoint Advisory Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at about $43,000. FMR LLC grew its stake in shares of Catalyst Pharmaceuticals by 24.2% during the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 822 shares in the last quarter. Finally, Covestor Ltd grew its stake in shares of Catalyst Pharmaceuticals by 768.0% during the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,316 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.